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Oral bioavailability is a key consideration in development of drug products, and the use of preclinical spe-
cies in predicting bioavailability in human has long been debated. In order to clarify whether any corre-
lation between human and animal bioavailability exist, an extensive analysis of the published literature
data was conducted. Due to the complex nature of bioavailability calculations inclusion criteria were
applied to ensure integrity of the data. A database of 184 compounds was assembled. Linear regression
for the reported compounds indicated no strong or predictive correlations to human data for all species,
individually and combined.
The lack of correlation in this extended dataset highlights that animal bioavailability is not quantita-
tively predictive of bioavailability in human. Although qualitative (high/low bioavailability) indications
might be possible, models taking into account species-speciﬁc factors that may affect bioavailability
are recommended for developing quantitative prediction.
 2013 Elsevier B.V. All rights reserved.1. Introduction
The understanding of the absorption of oral dosage forms is a
key consideration in drug development. Oral routes are preferred
for being less invasive and more physiological and due to ease of
administration and patient compliance. However, compared to
the direct entry of the drug to systemic circulation that is achieved
through intravenous dosing, additional elements affecting the
availability of the drug following oral administration must be con-
sidered. These may include potential for degradation in stomach or
gut lumen, metabolism in the gut wall and liver, permeability
through the gut wall and incomplete release of the drug from the
formulation. The molecular structure of the drug and constituents
of the dosage form can determine many of these processes and
they deﬁne how much of a drug reaches the systemic circulation.
With all of these factors in mind, the OrBiTo project is aiming to
deliver rational methods and a framework for predicting how oral-
ly-administered drugs will perform (OrBiTo, 2012). In doing so, it is
important to recognise some of the current practices related toestimation of the oral drug bioavailability in humans and their
validity.
Understanding oral bioavailability is not just a drug develop-
ment issue but it has regulatory implications as deﬁned by the
many agencies such as FDA in their guidance for industry
(FDA, 2003). These usually distinguish between the rate and
extent which the active ingredient or active moiety is absorbed
from a drug product and becomes available at the site of action.
Since measurement at the site of action is not practical, bioavail-
ability calculation for extravascular administration acts as a
surrogate to determine the amount of drug reaching site of
action relative to those from intravascular administration
(Sietsema, 1989).
Subtle differences in the methods of calculating bioavailability
exist which may give rise to variable results for a given drug or
drug formulation. Without an understanding of these assump-
tions, comparison of various bioavailability measures would not
be prudent. In the current drug development paradigm, adminis-
tration of drugs in various preclinical species prior to human
clinical studies is common for variety of reasons. It is often
assumed that data on drug absorption from animals could pro-
vide reasonable estimates of bioavailability in humans. However,
whilst similarity of permeability and fraction absorbed to gut
wall between animals and human is established (Chiou and Bar-
ve, 1998; Chiou et al., 2000; Chiou and Buehler, 2002; Cao et al.,
2006) there are considerable interspecies differences in ﬁrst-pass
gut and liver metabolism. These differences can prevent conclud-
ing a level of overall bioavailability in humans based on the
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bioavailability have previously been reported in the literature,
and although these seem to indicate that animal values are not
predictive of human bioavailability, they have mainly been
limited to small sets of measurements, or comparisons within
one species. In some instances queries have been raised regard-
ing the treatment, analysis and sources of the data forming
the reports. Furthermore, it is not clear whether formulations
have been matched when comparing human with animal
bioavailability; e.g., oral doses may have been given via solution
or suspension to animals while human studies make use of solid
formulations which might result in formulation-linked bioavail-
ability differences rather than solely a species difference. There
may also be differences in study design such as use of the same
or different study groups for oral and iv administration which
may cloud the comparisons. These issues should not be over-
looked when making comparisons.
We report an extensive analysis of the published data
conducted as part of OrBiTo project to clarify the relationships
between human and animal bioavailability, paying speciﬁc atten-
tion to those issues described above. It is expected that this report
contributes to providing an answer to the question that whether a
correlation exists between the bioavailability in animals and
humans and whether such animal data can be used for predicting
human bioavailability; quantitatively or qualitatively.Table 1
Inclusion criteria for studies.
1. Oral and intravenous data should be established in the same group
2. Species should fall under category of Mouse, Rat, Dog or Non-Human Primate
3. AUC should be calculated to inﬁnity or absorption phase should be complete
4. Original study data (no review articles) must be included when possible2. Methods
2.1. Calculation of bioavailability
The overall bioavailability is often considered as a composite
function of fraction released and absorbed into gut wall (Fabs), frac-
tion escaping ﬁrst-pass gut wall metabolism (FG) and fraction
escaping ﬁrst-pass hepatic metabolism (FH):
F ¼ Fabs  FG  FH ð1Þ
Calculation of oral bioavailability (F), and the deﬁnition of the
fraction absorbed Fabs (which is one of its three components), is
not uniﬁed. Pang and Rostami have recently commented on these
(2011). Whilst one may consider the total oral drug bioavailability
based on deducting the fraction ‘‘unabsorbed’’ (1  F) via analysis
of feces, in many cases the dose normalised relative area under
the curve (AUC) after oral and iv administration is used as a mea-
sure of oral bioavailability.
There are implications in certain situations for using each of the
above methods however in general they should produce the same
results. Disparities might occur when there are signiﬁcant ele-
ments of entero-hepatic recirculation or high ﬁrst-pass metabo-
lism in lung. When the Fabs is deﬁned as the fraction of given
dose that passes through the gut wall, the integration of all the
mass transfer (alongside the GI tract) over the time period that
absorption is happening may include the drug that originates from
entero-hepatic circulation. This leads to an apparent Fabs can be-
come higher than 1 when traditional comparison of AUC after iv
and oral administration is used to assess bioavailability (hence F
could be greater than 1).
Considering the differences between deﬁnitions used to deter-
mine F, it was essential to pay attention to methodologies used
for calculating oral bioavailability before making comparisons be-
tween various species.
2.2. Sources for human and animal bioavailability values
A number of reports have previously compared human and
animal bioavailability values for series of compounds. One ofthe commonly known comprehensive reports carried out by
Grass and Sinko (2002), utilising the dataset published by Siet-
sema (1989). There has been no attempt to expand the data
within the 2002 report with any additional data published since
then or reﬁne some ambiguities in the original report. Anecdotal
evidence indicated that the number of data points in the pub-
lished comparisons (within a scatter graph) were not consistent
with the number of compounds that appeared in the original
dataset. The reasons for this were not immediately clear from
the description given in the report. To assess the number of data
points and their consistency with original source, the scatter plot
of human vs. animal bioavailability in Grass and Sinko (2002)
was digitised using GetData Graph Digitizer v2.22 (Get Data
Graph Digitizer, 2012), and the extracted data compared to that
published in the original study by Sietsema (1989). In addition,
the relationships between human and animal bioavailability, re-
ported in this original database (Sietsema, 1989) were reviewed.
References sources were obtained where available and checked
against criteria developed for ‘‘inclusion’’ which ensured the val-
ues and the species were relevant to current study. Some studies
were marked as ‘Rodent’ which were considered too broad in
light of currently utilised preclinical species. Hence, all data
relating to species other than mouse, rat, dog and non-human
primates were discarded.
Additional compounds were identiﬁed using the human bio-
availability database published by Varma et al. (2010). Some infor-
mation on were obtained from other human vs. animal literature
reports (Chiou and Buehler, 2002; Cao et al., 2006; Akabane
et al., 2010). Where original data and references were not provided
in the publication, the authors were contacted and invited to
clarify the sources of information.
Finally, systematic literature searches being carried out using
PubMed and Google Scholar for the bioavailability values in human
and their corresponding animal data. Original references were
obtained and inspected in all cases.2.3. Inclusion and exclusion criteria
Inclusion criteria (Table 1) were applied to ensure integrity
of the data and consistency between various researchers con-
ducting the reviews. Mean bioavailability values were extracted
directly from the publications. If iv and oral data had not been
obtained from the same individuals and they were from differ-
ent studies, bioavailability measures were considered unreliable
due to potential effects of inter-subject variability. Where more
than one dose was reported, the bioavailability for the lowest
dose was selected in order to minimise the potential impact
of saturation effects. Information on formulations were
recorded. The details of strain and sex of animals utilised were
noted for each reference, along with parameters relating to the
compound type and use. Additional information were noted if
considered beneﬁcial to the aims and objectives of the current
investigation (e.g. number of subjects where more than one
reference was found) and recorded in a ‘comments section’ of
database. Studies relating to controlled release formulations
were discarded.
Fig. 1. Plot of oral bioavailability (F) in animal species vs. oral bioavailability in
humans (in percentage). Diamonds are for mouse, circles for rat, and triangles for
dog and squares for non-human primates (NHP).
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For compounds with more than one bioavailability study, the
weighted mean for the oral bioavailability was estimated by
x ¼
Pn
i¼1wixiPn
i¼1wi
ð2Þ
where xi was the mean oral bioavailability for the ith study, n in
the number of studies, and the weights (wi) were the number of
subjects in the ith study, respectively. For studies with an unknown
number of subjects, the assigned weights corresponded to the
median number of subjects employed in the rest of the studies,
with values of 6 and 5 for the human and animal studies,
respectively.
Linear regression was performed for oral bioavailability in
animal species (FAnimal,species) and human (FHuman) and the coefﬁ-
cient of determination (R2) and the linear regression equation
were recorded for each species and the whole dataset. A similar
analysis was performed by grouping the compounds by ion class
(FAnimal,ionclass and FHuman,ionclass), and formulations (FAnimal,formulation
and FHuman,formulation). In addition, accuracy of the FHuman prediction
from FAnimal,species data was assessed by the ratio between animal
and human oral bioavailability (RA/H) and average fold error
(afe), Eqs. (3) and (4), respectively, whereas, for evaluation of
the precision of the prediction, the concordance correlation
coefﬁcient (ccc) was calculated (Graham et al., 2012). All the
statistical calculations where performed with the Statistical
Toolbox within Matlab R2012a (The MathWorks Inc., Natick,
MA, USA) and Microsoft Excel 2010 (Microsoft Corporation,
Redmond, WA, USA).RA
H;i
¼ FAnimal;species;i
FHuman;i
ð3ÞAfe ¼ 10ð
1
nR logðRA
H;i
ÞÞ ð4Þ3. Results
3.1. Data extracted from previous reports of human vs. animal
bioavailability
Digitisation of the scatter plot of human vs. animal bioavailabil-
ity in the report by Grass and Sinko (2002) and comparisons to the
information within the tables provided by Sietsema (1989) con-
ﬁrmed that there were more data points than compounds in the
graph for all species (Table 2). It is worth noting that although Siet-
sema collated bioavailability data from the literature for over 400
drugs, the human versus animal correlations were limited to
approximately 70 compounds in total where the experimental bio-
availability values were available for human and at least one of the
other species.
Visual inspection of the tables, extracted data and the plot sug-
gests that multiple points may have been plotted for each com-
pound where a large range for bioavailability was reported,Table 2
Points extracted from Grass and Sinko plot.
Species Number of points expected Number of points extracted
Rodent 40 61
Dog 43 76
Primates 11 15further detail on the analysis of these data were not available for
inspection.3.2. Literature search and description of the dataset
The literature search resulted in a total of over 1000 studies,
published between 1969 and 2012, representing around 450
different compounds. The compounds with no FHuman and/or the
corresponding FAnimal,species data were removed from the dataset.
From the original dataset, only 184 different compounds with both
human and animal oral bioavailability were identiﬁed and 54 of
those compounds had more than one study for animal and/or hu-
man oral bioavailability. For the latter compounds, the weighted
mean was calculated as described above. Finally, the number of
paired datasets with both animal and human bioavailability by
species was 30, 122, 125 and 41 for the mouse, rat, dog and non-
human primates (NHP), respectively. In addition, FAnimal,species was
plotted against FHuman (Fig. 1) and the ﬁnal dataset is shown in Ta-
ble 3. Within species, the most frequent strains employed for the
oral bioavailability studies in animals were Sprague-Dawley and
Wistar for the rat (49% and 35%, respectively), Beagle and Mongrel
for the dog (66% and 19% respectively) and Rhesus and Cynomol-
gus monkey for the NHP (42% and 40%, respectively), whereas for
the mouse, no clear tendency was shown for the use of any
particular strain. In relation to ionic class, the majority of the
compounds in the dataset were basic followed by neutral, acidic
and zwitterionic, representing 50.0%, 24.5%, 15.8%, and 9.8% of
the total compounds, respectively. The predominant formulation
was solid (tablet and capsule) for human studies and liquid
(solution and suspensions) in the case of animal studies; however
for a large number of studies the formulations employed were not
informed.3.3. Correlation between animal and human bioavailability
As shown in Table 4, linear regression analysis revealed a poor
correlation for the overall animal and human oral bioavailability
Table 3
Interspecies oral bioavailability (F) for the selected compounds.
Compound Name Ionic class Mouse Rat Dog NHP Human
Mean F (%) Range F n Mean F (%) Mean F (%) Range F Mean F (%) Range F n Mean F (%) Range F n Mean F (%) Range F n
5-Fluorouracil Neutral 28.0 28.6 26–33 3
Acarbose Base 4.0 1.4
Acebutolol Base 61.0 34.0
Acetylsalicylate (Aspirin) Acid 35.0 45.0 48.5
Acyclovir Base 2.18 90.7 54.2
Adefovir Base 8.0 12.0
Alprazolam Acid 7.5 92.0
Amitriptyline Base 96.5 46.0
Amlodipine Base 100.0 100.0 88.0 64.0
Amosulalol Base 22.1 58.5 57.4 100.0
Amoxicillin Zwitterion 76.8 77.4
Antipyrine Neutral 73.0 100.0
Azathioprine Base 51.0 55.0
Azithromycin Base 46.0 97.0 37.0
Ceﬁxime Acid 52.2 52.3
Cefuroxime Axetil Acid 23.1 33.5
Chlorpheniramine Base 9.4 47.0
Clonazepam Base 33.0 90.0
Cyclosporine Neutral 40.0 20.8
Dapsone Base 100.0 93.0
Diazepam Base 86.0 95.0
Doxazosin Base 50.0 60.0 63.0
Erythomycin Base 14.5 14–15 2 52.0 1.9 32.6 32–35 2
Estradiol Valerate Neutral 4.3 7.8 0.3–9 2 8.7
Estramustine phosphate Neutral 54.3 43.7
Ethambutol Base 76.0 87.4 77.3–97.4 2
Ethimizol Neutral 32.4 12.8
Ethinylestradiol Neutral 3.0 8.1 7.5–9 2 0.6 41.9 36–59 4
Ethosuximide Neutral 74.0 83.0 91.0 93.0 100.0
Ethylmorphine Base 5.7 26.0 28.0
Etoposide Neutral 10.4 8.9–13.9 3 13.4 12.9 54.0 52–57.3 2
Felodipine Neutral 20.0 17.0 16.0
Fenﬂuramine Base 15.0 89.3
Fenoterol Base 0.6 0.4–0.8 2 1.5
Fexofenadine Zwitterion 2.4 3.8 2.6–4.6 3 6.6 41.0
Finasteride Neutral 92.0 80.0
Fleroxacin Zwitterion 78.8 88.5 100.0 99.9 99–100 3
Fluconazole Neutral 75.0 80.0 100.0 90.0
Flumazenil Neutral 28.0 22.3 15–27.8 2
Flunisolide Neutral 55.7 99.2 55.0 4.9 20.0
Flunitrazepam Neutral 69.0 85.0
Fluvastatin Acid 35.0 86.4 41.0 16.0 29.0
Foscarnet Acid 10.0 13.1 9.1–17.1 2
Fosfomycin Acid 29.0 32.2 28–37 2
Furosemide Acid 28.9 46.5 58.3 43.4–71 8
Gabapentin Zwitterion 79.0 79.0 80.0 40.1 60.0
Ganciclovir Neutral 10.0 100.0 8.8
Gatiﬂoxacin Zwitterion 60.5 98.5 96.0
Gitoxin Neutral 91.1 95.0
Glaziovine Base 98.5 84.3
Glyburide (Glibenclamide) Acid 14.7 85.3 82–89 3
Griseofulvin Neutral 3.9 51.2
Guanfacine Base 35.0 81.1
(continued on next page)
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Table 3 (continued)
Compound Name Ionic class Mouse Rat Dog NHP Human
Mean F (%) Range F n Mean F (%) Mean F (%) Range F Mean F (%) Range F n Mean F (%) Range F n Mean F (%) Range F n
Hydralazine Neutral 37.7 33.6 31.3–35.4 2
Hydrochlorothiazide Neutral 30.7 63.1 60.2–67.5 2
Ibuprofen Acid 90.0 100.0 100.0
Idazoxan Base 12.6 66.0 34.0
Ifosphamide/ Ifosfamide Neutral 40.0 88.3
Indapamide Neutral 98.0 99.0
Indomethacin Acid 63.7 91.9 89–100 2
Isosorbide dinitrate Neutral 40.0 27.6 19–48 6
Isosorbide-2-mononitrate Neutral 100.0 100.0
Isosorbide-5-mononitrate Neutral 71.5 98.4 93–100 5
Isoxicam Neutral 99.0 100.0
Itraconazole Neutral 27.1 16.6–34.9 2 55.0
Ketanserin Base 100.0 100.0 47.4 45–51 3
Ketorolac Acid 90.4 99.1 91–100 2 100.0 100.0 95.9 80.5–100 2
Lansoprazole Neutral 30.5 26.5 81.0
Levodopa Zwitterion 36.3 33.3
Levoﬂoxacin Zwitterion 87.6 99.0
Levonorgestrel Neutral 67.0 9.0 22.0 9.0 89.0
Lidocaine (Lignocaine) Base 7.1 31.0 25.0 25–25 2 27.8 12.6–37 4
Linezolid Neutral 95.0 95.0 100.0
Lisuride Base 28.0 5.0 14.0
Lithium carbonate Neutral 97.9 94.5
Losartan Acid 55.7 35.8
Melagatran Zwitterion 13.0 72.0 7.7
Meloxicam Neutral 94.0 95.0 100.0 91.0 89–97 2
Menogaril Acid 33.2 11.8 33.0 33.6
Mepindolol Base 1.5 40.0 82.1
Mercaptopurine Neutral 8.0 4–12 2 12.0
Metformin Base 34.1 60.6
Methadone Base 0.0 79.0 79–79 2
Methylprednisolone Neutral 35.1 49.4
Metoclopramide Base 71.9 49–91 2 75.3 58.1–84 4
Metolazone Neutral 80.0 49.9
Metoprolol Base 25.0 44.5 41–50 5
Midazolam Neutral 2.3 14.9 2.3–45 8 15.1 1.9 1.6–2.1 3 33.8 24–48 8
Morphine Base 12.1 6.5–14.9 3 19.6 17.9–23 2 36.5 26–47.1 5
Moxiﬂoxacin Zwitterion 78.0 78.0 91.0 48.5 45–52 2 82.0
Moxonidine Base 5.1 87.6
Nalbuphine Base 2.5 0.9–4.7 3 4.8 3.5–5.6 2 16.4
Naloxone Base 0.3 0.9
Naltrexone Base 0.8 91.5 100.0
Naproxen Acid 100.0 100.0
Naratriptan Base 71.0 95.0 63.0
Nefazodone Base 14.0 15.0
Nevirapine Neutral 91.0 93.0
Nicardipine Base 21.5 8.9 10.4 10.4 10.2–10.5 2
Nifedipine Neutral 9.3 50.0 43–63 7
Nimodipine Neutral 22.3 5.4
Nisoldipine Neutral 2.7 11.7 3.9
Nitrendipine Neutral 12.0 29.0 21.2
Nizatidine Base 72.4 94.4 96.7 94–100 2
Nomifensine Base 48.3 26.5
284
H
.M
usther
et
al./European
Journal
of
Pharm
aceutical
Sciences
57
(2014)
280–
291
Norfenﬂuramine Base 19.0 85.3
Nufenoxole (SC–27166) Base 96.0 26.0 85.0 100.0
Oﬂoxacin Zwitterion 77.8 100.0
Omeprazole Neutral 19.3 6.4–40.8 2 15.0 55.6 40–70 3
Ondansetron Base 7.2 6–8.6 2 57.0
Oseltamivir acid Acid 30.0 35.0 73.0 79.0
Oxazepam Zwitterion 72.3 56–88.5 2 40.0 22.1 92.8
Phenobarbital Acid 96.7 91.0 93.0 11–15.5 3
Phenoxymethylpenic–illin (Penicillin V) Acid 29.0 11.6 11.0 5.5 48.1
Phenytoin Acid 36.0 78.5 69.9–90 3
Physostigmin Base 2.0 4.9 3.2–8.2 2
Pindolol Base 80.0 73.0 85.0 85.0 86.0
Piroxicam Zwitterion 100.0 89.0 100.0
Pravastatin Acid 12.3 32.3 19.1
Prazosin Base 30.5 23–38 2 68.0
Prednisolone Neutral 55.0 82.0
Prednisone Neutral 38.0 77.3 69–80 3
Primaquine Base 25.0 96.0
Procainamide Base 85.0 80.9 75.3–83 2
Propoxyphene Base 25.3 18.0
Propranolol (±) Base 19.0 6.8 <1 22.0
Propranolol () Base 7.9 5.7–10.5 2 28.0
Propranolol (+) Base 17.8 16.1–19.9 2 19.4
Propylthiouracil Acid 88.0 77.0
Pyridostigmine Base 33.6 7.6 14.3–7.6 2
Quinidine Base 57.0 73.3 70.0
Rabeprazole Base 24.3 51.8
Ranitidine Base 73.0 54.4 52–60 2
Reboxetine Base 21.0 5.0 90.0 46.0 97.0
Recainam Base 51.0 89.0 97.0 70.3 67–73 2
Remoxipride Base 8.0 <1 94.0 94.9 93–96 2
Rifabutin Base 44.0 20.0
Rifampin Zwitterion 89.0 94.8
Risedronate Acid 2.9 0.6
Risperidone Base 22.0 65.9
Rosiglitazone Zwitterion 100.0 99.0
Rosuvastatin Acid 19.0 20.1
Salbutamol Base 85.0 51.2 50–53 2
Salicylate Acid 92.0 100.0 95.2
Saquinavir Base 42.2 6.5 0.7
Selegiline Base 8.1 4.3
Sildenaﬁl Base 17.0 33.5 54.0 40.4 38–41 2
Sitaﬂoxacin Zwitterion 30.9 51.2 92.7 89.0
Sitagliptin Base 76.0 100.0 68.0 87.0
Sotalol Base 84.1 100.0
Sparﬂoxacin Zwitterion 61.6 58.3–63.3 2 84.4 77–91.9 2 79.7 92.0
Sulﬁsoxazole Zwitterion 77.0 100.0
Sulpiride Base 13.4 82.5 35.5
Sumatriptan Base 37.0 56.2 54–58 2 14.0
Tacrolimus Acid 22.0 26.2 6.5 15.5 15–17.8 2
Talinolol Base 29.0 17.1–52.1 3 65.0 55–68.9 2
Tamsulosin Base 14.4 29.7 100.0
Terazosin Base 67.8 82.0
Terodiline Base 23.0 90.8 90–92 2
Tetrabenazine Base 84.0 4.9
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Table 3 (continued)
Compound Name Ionic class Mouse Rat Dog NHP Human
Mean F (%) Range F n Mean F (%) Mean F (%) Range F Mean F (%) Range F n Mean F (%) Range F n Mean F (%) Range F n
Theophylline Base 77.2 63.8–97.2 3 94.0 91–100 2 94.9 98.0 94–100 5
Tiagabine Acid 25.0 54.0 89.9
Timolol Base 29.0 61.0
Tinidazole Base 100.0 99.0
Tolterodine Base 14.2 11.0 60.5 43.0
Torsemide Acid 92.7 87.5–95.6 2 77.0 93.1 89–96 2
Tramadol Base 32.4 65.0 67.9
Trazodone Base 27.2 73.6 63–77 2
TRH Tartrate Base 1.5 12.6 2.0
Triazolam Neutral 19.0 16.0 53.0
Trovaﬂoxacin Zwitterion 68.0 58.0 85.0 89.1 87.6–91 2
Valproic Acid Acid 94.4 93.0 94.4 92.8–96 2
Vardenaﬁl Base 10.0 27.3 14.5
Venlafaxine Base 12.6 59.8 6.5 44.0
Verapamil (±) Base 14.5 13.8–15.2 2 2.5 23.9 18–38 3
Verapamil () Base 7.4 1.7 1.5–1.9 2 20.0
Verapamil (+) Base 4.1 21.1 20.6–21.6 2 50.0
Warfarin Acid 85.8 93.0
Xamoterol Base 23.2 8–34 2 4.6 4.5–4.8 3
Zalcitabine Base 30.0 93.4 86–100 3
Zanamivir Base 3.0 2.0
Zolmitriptan Base 41.0 79.0 42.8 39–49 2
Zolpidem Base 27.0 66.2 65.8–66.6 2
Zopiclone Base 44.0 100.0 76.9 76.7–77 2
F, oral bioavailability; Range, F, range for the mean bioavailability values for the studies; n, number of studies for the calculation of the weighted mean. References for the bioavailability studies can be found in the supplementary
material for the online version of this article.
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Table 4
Linear regression analysis, afe and animal/human oral bioavailability ratio.
Species Number of points Slope (b) Intercept (a) R2 ccc afe Median RA/H 5% lower percentile for RA/H 95% upper Percentile for RA/H
All 318 0.553* 33.114 0.342 0.548 0.647 0.866 0.082 2.771
Mouse 30 0.507** 39.478 0.253 0.444 0.593 0.784 0.058 2.784
Rat 122 0.544* 35.759 0.287 0.470 0.583 0.723 0.075 2.777
Dog 125 0.580* 26.433 0.374 0.605 0.845 0.990 0.236 3.254
NHP 41 0.691* 32.942 0.694 0.698 0.417 0.592 0.051 1.042
Regression equation, FHuman = b  FAnimal,species + a; R2, coefﬁcient of determination; ccc, concordance correlation coefﬁcient; afe, average fold error; RA/H, animal and human oral
bioavailability ratio.
* p value vs. constant model < 0.001.
** p value vs. constant model < 0.005.
Fig. 2. Plots for the linear regression analysis by separated by species (in percentages), the coefﬁcient of determination (R2) for the linear regression are shown in each plot.
(a) Mouse F vs. human F; (b) Rat F vs. human F; (c) Dog F vs. human F and (d) Non-human primates (NHP) F vs. human F.
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in the R2 value compared to the value from obtained from the
whole dataset, whereas for the mouse and rat data, R2 values
were lower than for the dog. In contrast, R2 value obtained for
the NHP was higher than the value for the overall dataset andfor every species in particular (Fig. 2). However, a prediction of
FHuman from FAnimal,species, employing the linear regression model,
resulted in wide prediction intervals (PI), as shown in Figs. 5
and 6. Afe calculations showed values below the unity for the
general dataset and for every species in particular. Calculated
Fig. 3. Box plots of median animal/human bioavailability ratios (RA/H) and interval between animal and human oral bioavailability. Triangles indicate 95% conﬁdence interval
(CI) for the median values; Dashed line (---), indicate the upper limit for outliers representation.
Fig. 4. Plots for the linear regression analysis by separated by ion class (in percentages), the coefﬁcient of determination (R2) for the linear regression are shown in each plot.
(a) Mouse F vs. human F; (b) Rat F vs. human F; (c) Dog F vs. human F and (d) Non-human primates (NHP) F vs. human F.
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Fig. 5. Plot of the linear regression analysis for the general dataset, animal vs.
human oral bioavailability. Diamonds are for mouse, circles for rat, and triangles for
dog and squares for non-human primates (NHP). Solid line (–), linear regression
line; Pointed line (  ), 95% conﬁdence interval (CI) for mean response; Dashed line
(---), 95% prediction interval (PI) for a future value.
Fig. 6. Plots for the linear regression analysis by classiﬁed by species (in percentages), the
Mouse F vs. human F; (b) Rat F vs. human F; (c) Dog F vs. human F and (d) Non-human prim
conﬁdence interval (CI) for mean response; Dashed line (---), 95% prediction interval (P
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lack of agreement between human and animal bioavailability
for all species, suggesting a lack of precision in any quantitative
prediction. In addition the median ratio between animal and hu-
man oral bioavailability (RA/H) showed similar results for the gen-
eral dataset and almost all the species. The dog, however, showed
a median value close to the unity (median RA/H = 0.990), but with
the highest interval of all the species (0.236 to 3.254 for the 5th
and 95th percentile, respectively) (Fig. 3). A similar scenario oc-
curs for the correlation analysis by ion class summarised in
Table 2 and Fig. 4. Acidic drugs showed the highest R2 value
(R2 = 0.549); followed by neutral and zwitterionic drugs, while
the lowest R2 value was for basic compounds (R2 = 0.212) (see
Tables 5 and 6).
Grouping compounds by formulation type (Solution or Solid)
shows no advantage over the weighted combination of data with
Solution and Solid showing similar R2 values (Solution R2 = 0.339,
Solid R2 = 0.328) to the overall relationship, all of which indicate
a poor correlation.4. Discussion
The digitisation and careful re-analysis of the Grass and Sinko
scatter plot raised a number of questions about the treatment ofcoefﬁcient of determination (R2) for the linear regression are shown in each plot. (a)
ates (NHP) F vs. human F. Solid line (–), linear regression line; Pointed line (  ), 95%
I) for a future value.
Table 5
Linear regression analysis by ionic class.
Species Number of points Slope (b) Intercept (a) R2
Acid 53 0.686* 26.295 0.549
Base 152 0.440* 35.891 0.212
Neutral 73 0.596* 30.897 0.409
Zwitterion 39 0.524* 44.592 0.343
Regression equation, FHuman = b  FAnimal,ionclass + a; R2, coefﬁcient of determination.
* p value vs. constant model < 0.001.
Table 6
Linear regression analysis by formulation type.
Species Number of
points
Slope
(b)
Intercept
(a)
R2
Solution 57 0.157 32.128 0.339
Solid (Capsule/Tablet/
Solid)
30 0.524 34.153 0.328
Regression equation, FHuman = b  FAnimal,formulation + a; R2, coefﬁcient of
determination.
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more data points (pair of human-animal bioavailability data) than
compounds due to multiple comparisons, not all points could be
readily identiﬁed in the associated database of Sitesema based on
our re-analysis. No further detail on how the data were treated
was given in the original review by Grass and Sinko and we could
not resolve the disparities. It is plausible that multiple points are
plotted to signify not just the mean values but also maximum
and minimum reported values, where a large range of bioavailabil-
ity had been observed. The combination of these factors (lack of
clear description of the methodology and the apparent mismatch
between the cited data and visualisation in the scatter plot) high-
light anecdotal and occasional questions posed by those who be-
lieve animal data could be predictive of human bioavailability.
These issues indicate that any comparisons between species
should make an effort to clarify data extraction methodology and
assumptions if the conclusions are to be used for deﬁning drug
development strategies with conﬁdence.
Our methodology involved combining multiple studies by
calculating a weighted mean which was less ambiguous when
constructing scatter plots and correlations. However, it had the
disadvantage that, where a large range of bioavailability values is
reported, this is not captured in the correlations. Alternative strat-
egies may involve separation of formulations, and a cursory analy-
sis was undertaken utilising the new dataset and a reported
formulation type (Solution or Solid). However, this is not an ideal
scenario where the data in humans and animals are generated by
different research groups using different materials but it is imprac-
tical to attempt to apply this formulation matching criteria due to
the limitations it imposes on the dataset. Another consideration for
correlations could be related to weighting each of the data points
based on the numbers subjects and animals used for each
combination.
The current dataset is, to the best of our knowledge, the largest
dataset published for investigating the correlation between animal
and human oral bioavailability. However, in addition to the com-
plexity of the data analysis, the process of the new literature anal-
ysis illuminated further issues with performing a correlation of this
magnitude on bioavailability data. For instance, we had to discard
some of datapoints from previously published correlation studies
due to more stringent inclusion criteria.
Clarity of the bioavailability studies in the literature varies
widely. The information included in some publications providethe full details of equations employed, and they are transparent
in describing methods of determination, formulations utilised
and full details of subjects. However, some other reports provided
minimal or in occasions no information in some aspects related to
the study and data analysis. Tracing used reference in other litera-
ture back to the original study proved problematic in some cases,
particularly where older papers were concerned. This led to exclu-
sion of reports from current dataset when the original report was
not available and not analysed by authors of the current report.
The regression analysis indicated that non-human primates are
the most predictive amongst other species for human bioavailabil-
ity (R2 of 0.7). Although the median relative bioavailability be-
tween animal species and human was unbiased for dog (median
value of the ratio being close to the unity), the wide range indi-
cated imprecision of the values as a predictive measure with con-
ﬁdence. The regression plot for dog (Fig. 2) highlights the above
conclusion showing the large degree of scatter and the poor corre-
lation coefﬁcient. For rat and mouse there was no indication of any
good correlation with the human data from any of the observed
results. The results questioned the default assumption that
bioavailability in rat or mouse can be a quantitative indication
for human bioavailability.
The dataset for non-human primates was far more limited than
for rat or dog, with only 41 data points available. This is not
surprising considering the higher cost and more restricted ethical
aspects associated with these studies. Further data could provide
more conﬁdence in relatively high correlations observed. However,
range of predicted bioavailability from non-human primates com-
pared to observed human values (Fig. 6) was wide and indicated
the qualitative rather than quantitative value.
When the formulations were matched, there was still an appar-
ent lack of correlation. In addition, when exploring the full dataset,
due to the use of solutions as the main route of administration in
animal studies (c.f. tablets in human), it might have been expected
that a bias towards higher bioavailability values in animal should
be seen. However, this was not the case, suggesting that the formu-
lations did not have a signiﬁcant impact on the correlations and bio-
availability (note that all extended release formulations were
excluded from the database). This conﬁrms that the notion that
other factors, such as metabolic differences between species, could
play a more important role in deﬁning disparities human vs. animal
drug bioavailability. Accounting for such differences may improve
understanding the differences and avoid over reliance on quantita-
tive value of animal to human extrapolation of bioavailability.5. Conclusion
An extended dataset to previously published reports was gener-
ated for animal vs. human bioavailability data with clear inclusion
criteria. This highlighted that there are not strong and predictive
linear correlations between overall and single species animal drug
bioavailability and human values. Classiﬁcation of high or low bio-
availability could be achieved by setting certain cut-off points how-
ever quantitativemodels of oral drug bioavailability should be built
for each species based on understanding the physiologic, metabolic
and transporter related information affecting bioavailability.Acknowledgements
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